132 related articles for article (PubMed ID: 17045763)
1. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells.
Chiu SJ; Hsu TS; Chao JI
Toxicol Lett; 2006 Dec; 167(2):122-30. PubMed ID: 17045763
[TBL] [Abstract][Full Text] [Related]
2. Expression of securin promotes colorectal cancer cell death via a p53-independent pathway after radiation.
Chiu SJ; Hsu TS; Chao JI
Chem Biol Interact; 2007 Dec; 170(3):153-61. PubMed ID: 17854787
[TBL] [Abstract][Full Text] [Related]
3. Depletion of securin increases arsenite-induced chromosome instability and apoptosis via a p53-independent pathway.
Chao JI; Hsu SH; Tsou TC
Toxicol Sci; 2006 Mar; 90(1):73-86. PubMed ID: 16338954
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells.
Liu HF; Hsiao PW; Chao JI
Chem Biol Interact; 2008 Oct; 176(1):48-57. PubMed ID: 18760266
[TBL] [Abstract][Full Text] [Related]
5. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.
Atallah D; Marsaud V; Radanyi C; Kornprobst M; Rouzier R; Elias D; Renoir JM
Int J Hyperthermia; 2004 Jun; 20(4):405-19. PubMed ID: 15204521
[TBL] [Abstract][Full Text] [Related]
6. The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells.
Chao JI; Liu HF
Mol Pharmacol; 2006 Jan; 69(1):154-64. PubMed ID: 16219911
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
8. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
[TBL] [Abstract][Full Text] [Related]
9. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.
Hsu TS; Chen C; Lee PT; Chiu SJ; Liu HF; Tsai CC; Chao JI
Cancer Chemother Pharmacol; 2008 Oct; 62(5):799-808. PubMed ID: 18193228
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.
Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
Biochem Pharmacol; 2007 Jun; 73(11):1715-26. PubMed ID: 17343830
[TBL] [Abstract][Full Text] [Related]
11. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
13. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
14. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis.
Bernal JA; Luna R; Espina A; Lázaro I; Ramos-Morales F; Romero F; Arias C; Silva A; Tortolero M; Pintor-Toro JA
Nat Genet; 2002 Oct; 32(2):306-11. PubMed ID: 12355087
[TBL] [Abstract][Full Text] [Related]
15. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
Yokoo S; Masuda S; Yonezawa A; Terada T; Katsura T; Inui K
Drug Metab Dispos; 2008 Nov; 36(11):2299-306. PubMed ID: 18710896
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
Chiu SJ; Lee YJ; Hsu TS; Chen WS
Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
[TBL] [Abstract][Full Text] [Related]
17. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling.
Mitchell C; Kabolizadeh P; Ryan J; Roberts JD; Yacoub A; Curiel DT; Fisher PB; Hagan MP; Farrell NP; Grant S; Dent P
Mol Pharmacol; 2007 Sep; 72(3):704-14. PubMed ID: 17578896
[TBL] [Abstract][Full Text] [Related]
18. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells.
Dornetshuber R; Heffeter P; Kamyar MR; Peterbauer T; Berger W; Lemmens-Gruber R
Chem Res Toxicol; 2007 Mar; 20(3):465-73. PubMed ID: 17326668
[TBL] [Abstract][Full Text] [Related]
19. Taiwanin A induced cell cycle arrest and p53-dependent apoptosis in human hepatocellular carcinoma HepG2 cells.
Ho PJ; Chou CK; Kuo YH; Tu LC; Yeh SF
Life Sci; 2007 Jan; 80(5):493-503. PubMed ID: 17182066
[TBL] [Abstract][Full Text] [Related]
20. Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression.
Song JD; Kim KM; Kim KH; Kim CD; Kim JM; Yoo YH; Park YC
Int J Oncol; 2008 Dec; 33(6):1299-306. PubMed ID: 19020764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
